SERPINF2
Basic information
Region (hg38): 17:1742836-1755265
Previous symbols: [ "PLI" ]
Links
Phenotypes
GenCC
Source:
- alpha-2-plasmin inhibitor deficiency (Supportive), mode of inheritance: AR
- alpha-2-plasmin inhibitor deficiency (Strong), mode of inheritance: AR
- alpha-2-plasmin inhibitor deficiency (Limited), mode of inheritance: AD
- alpha-2-plasmin inhibitor deficiency (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Alpha-2-plasmin inhibitor deficiency | AD/AR | Hematologic | Anti-fibrinolytic agents or FFP can be used to treat bleeding episodes, and to and prevent patients hemorrhagic complications in those who are undergoing surgical interventions; Intramedullary hematoma is also a common feature, and awareness of this potential manifestation can be beneficial in order to institute efficient treatment; Heterozygotes may also have (milder) manifestations | Hematologic | 82839; 156196; 89324; 7095605; 2496145; 2572590; 1806461; 9880645; 10583218; 11472338; 19141165; 19593116; 21873355 |
ClinVar
This is a list of variants' phenotypes submitted to
- Abnormal bleeding (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SERPINF2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 10 | 13 | ||||
missense | 20 | 30 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 1 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 1 | 6 | 7 | |||
non coding | 6 | |||||
Total | 1 | 1 | 20 | 16 | 13 |
Variants in SERPINF2
This is a list of pathogenic ClinVar variants found in the SERPINF2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
17-1745000-C-T | not specified | Benign (Nov 12, 2018) | ||
17-1745031-G-C | not specified | Uncertain significance (Jan 03, 2022) | ||
17-1745172-C-T | Abnormal bleeding | Uncertain significance (Feb 01, 2019) | ||
17-1745189-C-T | SERPINF2-related disorder | Likely benign (May 02, 2018) | ||
17-1745208-C-T | not specified | Benign (-) | ||
17-1745218-T-G | Likely benign (Dec 05, 2018) | |||
17-1745328-C-T | SERPINF2-related disorder | Likely benign (Sep 19, 2019) | ||
17-1745331-A-G | Likely pathogenic (Jul 05, 2022) | |||
17-1745341-C-T | SERPINF2-related disorder | Benign (Dec 31, 2019) | ||
17-1745342-G-A | not specified | Uncertain significance (Apr 19, 2024) | ||
17-1745346-C-T | not specified | Uncertain significance (Dec 03, 2021) | ||
17-1745347-G-A | Likely benign (Jul 13, 2018) | |||
17-1745702-C-T | Likely benign (Dec 31, 2019) | |||
17-1745712-C-G | not specified | Uncertain significance (Jul 11, 2023) | ||
17-1745728-C-T | not specified | Benign (-) | ||
17-1745738-C-A | not specified | Uncertain significance (Aug 04, 2023) | ||
17-1745766-C-A | not specified | Uncertain significance (Aug 15, 2023) | ||
17-1745790-C-G | not specified | Uncertain significance (Jan 23, 2023) | ||
17-1745793-G-A | not specified | Likely benign (May 04, 2022) | ||
17-1745899-C-A | Uncertain significance (Jun 01, 2023) | |||
17-1745903-G-A | not specified | Conflicting classifications of pathogenicity (Jul 29, 2023) | ||
17-1745973-A-G | Benign (Nov 12, 2018) | |||
17-1746874-C-T | Benign (Nov 12, 2018) | |||
17-1747063-G-A | SERPINF2-related disorder | Benign (Feb 07, 2018) | ||
17-1747123-G-A | not specified | Uncertain significance (Dec 18, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SERPINF2 | protein_coding | protein_coding | ENST00000324015 | 9 | 12433 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0136 | 0.985 | 125731 | 0 | 16 | 125747 | 0.0000636 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.23 | 229 | 288 | 0.796 | 0.0000181 | 3197 |
Missense in Polyphen | 47 | 86.849 | 0.54117 | 1006 | ||
Synonymous | -0.130 | 135 | 133 | 1.01 | 0.00000943 | 1008 |
Loss of Function | 2.83 | 7 | 21.0 | 0.334 | 0.00000100 | 210 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000190 | 0.000182 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000218 | 0.000163 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000712 | 0.0000439 |
Middle Eastern | 0.000218 | 0.000163 |
South Asian | 0.0000654 | 0.0000653 |
Other | 0.000654 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Serine protease inhibitor. The major targets of this inhibitor are plasmin and trypsin, but it also inactivates matriptase-3/TMPRSS7 and chymotrypsin. {ECO:0000269|PubMed:15853774}.;
- Disease
- DISEASE: Alpha-2-plasmin inhibitor deficiency (APLID) [MIM:262850]: An autosomal recessive disorder resulting in severe hemorrhagic diathesis. {ECO:0000269|PubMed:10583218, ECO:0000269|PubMed:2572590}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Complement and coagulation cascades - Homo sapiens (human);Blood Clotting Cascade;Dengue-2 Interactions with Complement and Coagulation Cascades;Dengue-2 Interactions with Blood Clotting Cascade;Complement and Coagulation Cascades;Dissolution of Fibrin Clot;Platelet degranulation ;Response to elevated platelet cytosolic Ca2+;Platelet activation, signaling and aggregation;Hemostasis
(Consensus)
Recessive Scores
- pRec
- 0.535
Intolerance Scores
- loftool
- 0.0313
- rvis_EVS
- -0.78
- rvis_percentile_EVS
- 13.05
Haploinsufficiency Scores
- pHI
- 0.222
- hipred
- Y
- hipred_score
- 0.505
- ghis
- 0.472
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.920
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | High | Medium | High |
Cancer | High | Medium | High |
Mouse Genome Informatics
- Gene name
- Serpinf2
- Phenotype
- homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- regulation of blood vessel diameter by renin-angiotensin;platelet degranulation;acute-phase response;response to organic substance;negative regulation of plasminogen activation;negative regulation of endopeptidase activity;collagen fibril organization;positive regulation of collagen biosynthetic process;fibrinolysis;positive regulation of cell differentiation;positive regulation of transcription by RNA polymerase II;positive regulation of JNK cascade;blood vessel morphogenesis;positive regulation of smooth muscle cell proliferation;positive regulation of stress fiber assembly;negative regulation of fibrinolysis;positive regulation of ERK1 and ERK2 cascade;positive regulation of transforming growth factor beta production;positive regulation of cell-cell adhesion mediated by cadherin
- Cellular component
- extracellular region;fibrinogen complex;extracellular space;cell surface;platelet alpha granule lumen;collagen-containing extracellular matrix;extracellular exosome;blood microparticle
- Molecular function
- protease binding;endopeptidase inhibitor activity;serine-type endopeptidase inhibitor activity;protein binding;protein homodimerization activity